arrow
T

Tatsuki Ikoma

Kansai Medical University
H指数:5
被引数:121

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical trajectory of KRAS G12C-mutated advanced non-small cell lung cancer: a single-center cohort study in Japan

KRAS G12C突变型晚期非小细胞肺癌的临床轨迹:一项日本单中心队列研究

2026-05-010
PRE
Why Cemiplimab? Defining a Unique Therapeutic Niche in First-Line Non-Small-Cell Lung Cancer with Ultra-High PD-L1 Expression and Squamous Histology

为什么选择Cemiplimab?在PD-L1表达超高水平且伴有鳞状组织学的非小细胞肺癌一线治疗中定义一个独特的治疗定位

Cancers
IF4.4
2026-01-170
OAAI
Efficacy and Safety of Chemoimmunotherapy in Patients With Advanced Non-small Cell Lung Cancer With Pre-existing Interstitial Pneumonia and Low PD-L1 Expression
2025-11-011
PRE
Combined effects of slow movement training with tonic force generation and aerobic exercise prior to cancer therapy in patients with lung cancer (START-lung): a pilot feasibility trial

肺癌患者癌症治疗前的慢速运动训练与持续力量生成及有氧运动的联合效应(START-lung):一项可行性试点试验

2025-10-030
OAAI
Efficacy and safety of taxane plus ramucirumab for advanced gastric cancer after chemotherapy plus nivolumab

紫杉类药物联合ramucirumab治疗化疗联合nivolumab后进展的晚期胃癌的疗效与安全性

2025-08-070
OA
The impact of antibiotic use on ICI plus chemotherapy versus chemotherapy in NSCLC patients with PD-L1 expression of 1% to 49%

PD-L1表达为1%至49%的NSCLC患者中,抗生素使用对ICI联合化疗与化疗的影响

2024-12-010
PRE
Impact of TTF-1 Expression on the Prognostic Prediction of Patients with Non-Small Cell Lung Cancer with PD-L1 Expression Levels of 1%to 49%, Treated with Chemotherapy vs. Chemoimmunotherapy: A Multicenter, Retrospective Study

TTF-1表达对PD-L1表达水平为1%至49%的非小细胞肺癌患者预后预测的影响:化疗与化疗免疫治疗的多中心回顾性研究

2024-10-250
OA
TRESBIEN (OGSG 2101): encorafenib, binimetinib and cetuximab for early recurrent stage II/III BRAF V600E-mutated colorectal cancer
2022-12-082
OA